Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302
July 26, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, July 26, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the 2023 Ophthalmology Innovation Summit
July 24, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, July 24, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Feature at the American Society of Retina Specialists 2023 Annual Meeting
July 13, 2023 06:00 ET
|
Opthea Limited
Podium presentation on the pharmacokinetics and safety of OPT-302 in retinal vascular diseasesParticipation in “Live From ASRS” virtual KOL discussion on market trends and new treatments in wet AMD...
Opthea Announces Departure of Chief Medical Officer and Appointment of Senior Medical Advisor
July 10, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, July 10, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Appoints Anshul Thakral as Non-Executive Director of the Board
June 08, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, June 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Present at the Jefferies 2023 Healthcare Conference
May 25, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, May 25, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea to Participate in EF Hutton Hosted Discussion on OPT-302 and the Wet AMD Market
May 17, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, May 17, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Present at the JMP Securities Life Sciences Conference
May 08, 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, May 08, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea To Participate at the H.C. Wainwright BioConnect Conference at NASDAQ
April 28, 2023 05:30 ET
|
Opthea Limited
MELBOURNE, Australia, April 28, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT; ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...
Opthea Receives A$8.7 million R&D Tax Incentive
March 07, 2023 06:00 ET
|
Opthea Limited
MELBOURNE, Australia, March 07, 2023 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; Nasdaq:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and...